A study led by researchers at Sylvester Comprehensive Cancer Center suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Downloadable video is available.
One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory tract. But does that mean that it is no longer present in the body? To find out, a team from the Institut Pasteur specialized in HIV, in collaboration with a French public research institute, the Alternative Energies and Atomic Energy Commission (CEA), conducted a study on lung cells in an animal model.
According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.
Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumour in cancer patients who do not respond to any other current therapies.
A special report published today in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.
Realizing the full potential of macrophage therapies relies on being able to see what these cellular allies are doing inside our bodies, and a team of Penn State researchers may have developed a way to watch them do their thing.
Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.
Researchers at the Francis Crick Institute, working with Imperial College London, King’s College London and University of Cambridge, have shown that an influx of water and ions into immune cells allows them to migrate to where they’re needed in the body.
Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes.
In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who do not develop MS.
As one of the most insidious diseases in the world, cancer has few treatments that work to eradicate it completely. Now, a new ground-breaking approach pioneered by two researchers working at the University of Missouri’s Roy Blunt NextGen Precision Health building shows promising results in preventing lung cancer caused by a carcinogen in cigarettes — a discovery that immunologists Haval Shirwan and Esma Yolcu rank among the most significant of their careers.
A study that assesses the effects of hypochlorous acid (HOCI), commonly known as bleach, as it is generated during the immune response of a cell (phagocytosis) when fighting a common fungal pathogen, Candida albicans, reveals that HOCI is a potent killing agent. The laboratory finding is highlighted in the journal mBio.
La inmunoterapia aprovecha el sistema inmunitario del organismo para combatir el cáncer. El tratamiento con linfocitos T con receptor quimérico para el antígeno (tratamiento con linfocitos T-CAR) es una forma de inmunoterapia en la que los profesionales de atención médica extraen las células T de una persona (conocidas como linfocitos que participan en la respuesta del sistema inmunitario) y las modifican genéticamente para que produzcan receptores quiméricos para el antígeno. A continuación, estos linfocitos T-CARse reintroducen en el torrente sanguíneo del paciente, donde se dirigen a las células cancerosas y las destruyen.
العلاج المناعي يسخر جهاز المناعة في الجسم لمحاربة السرطان. العلاج بالخلايا التائية المستقبلة للمستضدات الخيمرية (العلاج بخلايا CAR-T) هو شكل من أشكال العلاج المناعي الذي يقوم فيه أخصائيو الرعاية الصحية بإزالة الخلايا التائية للشخص — خلايا الدم البيضاء المعروفة باسم الخلايا اللمفية التي تشارك في استجابة الجهاز المناعي — وتعديلها وراثيًا لإنتاج مستقبلات المستضد الخيمرية (CARs). يتم بعد ذلك حقن الخلايا التائية المستقبلة للمستضدات الخيمرية (CAR-T) مرة أخرى في مجرى دم المريض، حيث تستهدف الخلايا السرطانية وتقتلها.
A new study from researchers at Wake Forest University School of Medicine shows that dopamine release in the human brain plays a crucial role in encoding both reward and punishment prediction errors.
Researchers, led by University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), discovered distinct mechanisms controlling different types of immune cells, and found that, by precisely targeting these mechanisms, they could selectively eliminate ‘problematic cells’ and reshape the skin's immune landscape.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found certain immune cells can still fight cancer even when the cancer cells lack an important protein that the immune system relies on to help track down cancer cells.
Hospital germs and pathogens are not always transmitted directly from person to person. They can also spread via germ-contaminated surfaces and objects.
Traditional cancer treatments such as chemotherapy and radiation can come with collateral damage. In the process of killing cancer, the treatments harm normal cells, too, leading to both short- and long-term side effects. Even today’s targeted drugs and immunotherapy can have effects on normal tissues.
Messenger bubbles produced by human cells can pick up bacterial products and deliver them to other cells, University of Connecticut researchers report in the Nov. 16 issue of Nature Cell Biology.
In a new Cell study, scientists at La Jolla Institute for Immunology (LJI) and Massachusetts General Hospital, Harvard Medical School, show how a protein called IKAROS helps "weave" the genome.
Scientists at UChicago discover that trans-vaccenic acid (TVA), a fatty acid found in beef, lamb, and dairy products, improves the ability of immune cells to fight tumors.
HIV (human immunodeficiency virus), the virus that causes AIDS (acquired immunodeficiency syndrome), can hide in the body for many years before symptoms appear.
O HIV (vírus da imunodeficiência humana) que causa a AIDS (síndrome de imunodeficiência adquirida) pode ficar oculto no corpo por muitos anos antes da manifestação dos sintomas.
El VIH (virus de la inmunodeficiencia humana), el virus que causa el SIDA (síndrome de inmunodeficiencia adquirida), se puede esconder en el organismo durante muchos años antes de que aparezcan los síntomas.
روتشستر، مينيسوتا – إن فيروس نقص المناعة البشري، الذي يسبب الإيدز (مرض نقص المناعة البشري المكتسب) بإمكانه أن يختفي في الجسم عدة سنوات قبلما تظهر الأعراض. وخلال هذا الوقت، فإنه يقضي على جزء من الجهاز المناعي دون أن نشعر. لذا فإن هدفنا هو اكتشاف فيروس نقص المناعة البشري قبلما تظهر الأعراض، مما يجعل الاختبارات الروتينية ضروريةً كي يعرف المرضى أنهم مصابون وكي يتسنى علاجهم، وهذا ما أوضحته الدكتورة ستيسي ريزا خبيرة الأمراض المُعدية والباحثة في فيروس نقص المناعة البشري لدى مايو كلينك.
Cleveland Clinic researchers analyzed genes and brain tissue of patients with Alzheimer’s and found that differences in brain immunometabolism – the interactions between the immune system and the ways cells create energy – may contribute to women’s increased risk for the disease and its severity.
Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for relapsed and recurrent pediatric leukemia and lymphomas, but not brain and solid tumors.
Immunologists found the difference between antibodies that react to birch pollen allergens in healthy people and patients with allergies. The authors also found out why not all classes of antibodies can protect against allergies. The results were published in Allergy.
Clarivate calls these scientists "pioneers," noting that ranking on the Highly Cited Researchers list is a sign that a scientist has published significant findings and influenced their field of study.
St. Jude scientists mapped the gene regulatory networks responsible for progressive differentiation states of tumor-infiltrating T cells, using a technology known as single-cell CRISPR screening to knock out or genetically perturb multiple genes potentially involved.
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
An international team has for the first time researched the longevity of neutralizing antibodies in HIV-1-infected people. Currently, it is assumed that an HIV-1 vaccine can only be effective if it produces these antibodies in vaccinated humans.
A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
The James P. Allison Institute at MD Anderson hosted its inaugural scientific symposium on Nov. 10, bringing together more than 400 leading scientists in immunotherapy and immunobiology.